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Abstract
Background: Clinical practice guidelines are not uniformly successful in influencing clinicians'
behaviour toward best practices. Implementability refers to a set of characteristics that predict ease
of (and obstacles to) guideline implementation. Our objective is to develop and validate a tool for
appraisal of implementability of clinical guidelines.
Methods: Indicators of implementability were identified from the literature and used to create
items and dimensions of the GuideLine Implementability Appraisal (GLIA). GLIA consists of 31
items, arranged into 10 dimensions. Questions from 9 of the 10 dimensions are applied individually
to each recommendation of the guideline. Decidability and Executability are critical dimensions.
Other dimensions are Global, Presentation and Formatting, Measurable Outcomes, Apparent
Validity, Flexibility, Effect on Process of Care, Novelty/Innovation, and Computability. We
conducted a series of validation activities, including validation of the construct of implementability,
expert review of content for clarity, relevance, and comprehensiveness, and assessment of
construct validity of the instrument. Finally, GLIA was applied to a draft guideline under
development by national professional societies.
Results: Evidence of content validity and preliminary support for construct validity were obtained.
The GLIA proved to be useful in identifying barriers to implementation in the draft guideline and
the guideline was revised accordingly.
Conclusion: GLIA may be useful to guideline developers who can apply the results to remedy
defects in their guidelines. Likewise, guideline implementers may use GLIA to select implementable
recommendations and to devise implementation strategies that address identified barriers. By
aiding the design and operationalization of highly implementable guidelines, our goal is that
application of GLIA may help to improve health outcomes, but further evaluation will be required
to support this potential benefit.
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Background
Tremendous resources have been invested in the develop-
ment and implementation of clinical practice guidelines
over the past 15 years [1-3]. In spite of these efforts, how-
ever, guidelines are not uniformly successful in improving
care and several instances of implementation failure have
been described, some resulting in substantial waste of
time and resources [4-6]. In many cases, implementation
failures have been related to factors extrinsic to the guide-
line itself – e.g., organizational and provider-specific
obstacles inherent in a particular system of care that inter-
fere with implementation success. In other cases, how-
ever, factors intrinsic to the guideline have contributed to
implementation failure, e.g., ambiguity, inconsistency,
and incompleteness [7,8]. We believe it is particularly
important to identify these intrinsic factors, because in
many cases they can be ameliorated or fully remedied by
guideline authors while the guideline is being developed.
If these problems are not captured during guideline devel-
opment, they must be addressed during implementation.
Guideline implementation involves "the concrete activities
and interventions undertaken to turn policies into desired
results" [9]. We define implementability to refer to a set of
characteristics that predict the relative ease of implemen-
tation of guideline recommendations. Measures of suc-
cessful implementation include improved adherence to
guideline-prescribed processes of care and, ultimately,
improved patient outcomes. Indicators of implementabil-
ity, on the other hand, focus on the ease and accuracy of
translation of guideline advice into systems that influence
care. In this paper, we describe a tool for appraisal of
implementability that is intended to help anticipate barri-
ers to implementation success. We first delineate the proc-
ess by which indicators of implementability were chosen.
Then we describe the steps we took in the preliminary val-
idation of the evolving instrument and show an example
of its application. Finally, we discuss how the instrument
might be used in practice.
Methods
Instrument development
The first step in the measurement of implementability was
to define its attributes. From a broad-based literature
search, we identified several key papers and book chapters
that describe the impact of a variety of factors on success
of implementation. The report from the Institute of Med-
icine [9] included general definitions and several high
level constructs relevant to implementation. Thorsen and
Mäkelä [10] described critical factors in implementation
strategy that facilitate use of guidelines and overcome bar-
riers to adoption. Solberg et al. asked expert implementers
about implementation success factors and identified 83
variables grouped into 5 clusters [11]. Applying diffusion
of innovation theory, Grilli and Lomas identified guide-
line complexity, trialability, and observability as critical
factors for successful implementation [12]. Grol and col-
leagues found that vagueness, controversy, demand for a
change in routines, and absence of an evidence-base dif-
ferentiated guidelines that were not followed from those
that were [13]. Finally, we examined 3 instruments for
appraisal of guideline quality – Cluzeau's 37-item instru-
ment [14], the AGREE instrument [15], and Shaneyfelt's
Guideline Quality Appraisal Questionnaire [16]– and
extracted factors from each that addressed
implementability.
The authors eliminated redundant factors, i.e., those that
appeared in several sources or represented concepts that
were subsumed by others, through open discussion and
consensus. Factors that indicated guideline quality but
not implementability were excluded. We decided early on
to focus the GLIA on factors that were intrinsic to the
guideline, because they could be addressed centrally by a
guideline development committee. Thus, we eliminated
many factors related to Solberg's medical group character-
istics, organizational capability for change, infrastructure
for implementation, and external environment. Extrinsic
items relating to a recommendation's effect on the process
of care and items relating to the novelty or innovation of
a guideline statement were retained in the instrument
because developers can anticipate these barriers and offer
potential strategies for implementation success.
All remaining factors were grouped into categories of
related constructs, hereafter referred to as dimensions. We
then devised specific questions to characterize each
dimension and phrased them so that negative responses
identified barriers. These questions ultimately became
items of the instrument. We iteratively refined the items,
further clarified definitions, and re-categorized items into
the most appropriate dimensions.
Validation
To explore the construct of implementability and its
measurement, we carried out a series of validation activi-
ties. The steps are summarized in Table 2 and are
described below in the sequence in which they were car-
ried out. Concomitant with these validation activities, the
GLIA instrument underwent iterative refinement and
revision.
Table 1: GLIA response options.
Y The recommendation meets this criterion fully.
N The recommendation does not meet this criterion.
? Rater is unable to address this question because of 
insufficient knowledge or experience in this area.
NA Criterion is not applicable to this recommendation.BMC Medical Informatics and Decision Making 2005, 5:23 http://www.biomedcentral.com/1472-6947/5/23
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Results
Final instrument
The table shown in [Additional file 1] summarizes the 10
dimensions of the instrument and their definitions. (The
GLIA instrument is available for download at http://
ycmi.med.yale.edu/GLIA.) Of the 31 items in GLIA, the
first dimension (Global) contains 7 items that relate to
the guideline as a whole. The remainder of the
dimensions focus on the individual recommendation as
the unit of implementability, since a single guideline may
contain recommendations that vary widely in their imple-
mentability. For each GLIA item, each recommendation is
rated using one of four response options (see Table 1).
Additional comments that explain each response are
encouraged. GLIA users should discuss all divergent rat-
ings and try to achieve consensus. Any items scored with
"?" should be resolved: often, this requires the help of an
expert in the guideline's topic area.
When any GLIA item is assigned an "N" response, its cor-
responding barrier to implementation is recorded on the
summary sheet with a brief description of why the recom-
mendation failed the criterion (see Figure 1). Examination
of the barriers recorded on the summary sheet should pro-
vide an understanding of predicted impediments to
implementation of the recommendation. The summary
sheet also contains a column where suggested remedies
can be described.
Validation
Step 1: Evaluation of implementability as a concept that is 
understood by experts
In April 2002, the Conference on Guideline Standardiza-
tion (COGS) brought together 23 national and interna-
tional leaders in guideline development, dissemination
and implementation [17]. This gathering provided the
opportunity to explore the concept of implementability.
We selected 3 recommendations for review by the experts
based on the following criteria:
• Each recommendation concerned a common clinical
problem generally understood by the attendees.
• The three recommendations as a group represented a
broad range of implementation challenges.
Using our own global subjective judgment of imple-
mentability, one of the recommendations was considered
to be straightforward to implement, another was consid-
ered to be quite difficult, and the remaining recommenda-
tion was considered to occupy an intermediate position.
The recommendations we selected concerned: aspirin
therapy in management of acute myocardial infarction
[18], diagnosis of urinary tract infection in young children
with unexplained fever [19], and evaluation of unex-
plained syncope [20].
Divided into 2 groups (10 individuals with considerable
experience in guideline implementation in one group, 11
individuals experienced in guideline development and
dissemination in the other), participants were asked to
rank the relative implementability of the guideline recom-
mendations. After discussion, each group came to a con-
sensus ranking of the three recommendations'
implementability. These rankings were consistent
between the two groups and also with the authors' expec-
tation. Both groups agreed that the aspirin recommenda-
tion would be easiest to implement and the syncope
algorithm would be most challenging.
This step provided support for our basic assumption that
the construct of implementability is real. Moreover,
implementability varies among recommendations in a
way that can be systematically recognized by experts.
Table 2: Summary of validation activities.
Step Process Purpose or Validity Type Results
1 Ranking of implementability of 3 
recommendations by experts at COGS
Validity of the construct of implementability Consistent ranking
2 Guideline review with early GLIA versions To refine GLIA Demonstrate feasibility of measurement of 
implementability
3 Expert review of GLIA items and 
dimensions by HL7 experts
Content validity of GLIA GLIA items rated generally as relevant and 
clear. Two new items were added, 
definitions were clarified, and explanatory 
material was added.
4 Review of the recommendations ranked in 
Step 1
Construct validity of GLIA GLIA assessment of these three guidelines 
was consistent with experts' rankings of 
implementability (Step 1). Barriers to 
implementation were explicitly identified.BMC Medical Informatics and Decision Making 2005, 5:23 http://www.biomedcentral.com/1472-6947/5/23
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Step 2- Initial guideline review with early GLIA versions
The authors next tested an early version of GLIA with a
convenience sample of 20 guideline recommendations.
These reviews provided our first experience using the GLIA
in practice and led us to identify areas of rating contro-
versy. Early attempts to apply a simple numeric scoring
system failed because all the items were not of equal
importance. In addition, we recognized the advantage of
qualitative rating in understanding specific barriers to
implementation. We appreciated the importance of
including a variety of expertise among members of the
GLIA team. This experience led to refinement of the
instrument, as well as to a deeper understanding of the
optimal process for conducting a review using GLIA.
The 20 replications of our process seemed quite adequate
to provide us with assurance that creating an instrument
to assess implementability was a feasible goal. They also
gave us a view of the problems still to be addressed.
Step 3 - content validation: Expert review of GLIA items and 
dimensions
To investigate the content validity of the draft GLIA, we
systematically examined each item's clarity, its relevance
to its superordinate dimension, and the comprehensive-
ness of the GLIA as a whole [21]. We prepared a Question-
naire for Expert Review on which relevance and clarity
ratings were scored on a four point scale, with higher
numbers representing greater relevance and greater clarity.
We distributed the Questionnaire to volunteers attending
Example of a GLIA Summary Report on draft recommendations from a guideline for diagnosis and management of otitis media  with effusion Figure 1
Example of a GLIA Summary Report on draft recommendations from a guideline for diagnosis and management of otitis media 
with effusion.
Recommendation 1a: Clinicians should use pneumatic otoscopy as the primary diagnostic method for OME. OME
should be distinguished from AOM.
Criterion failed / Barrier Specifics Suggested Remedy
13) Cannot be carried out by current non-performers
without substantial increases in provider time, staff,
equipment, etc. (Effects on Process of Care)
Pneumatic otoscopy requires
acquisition of new equipment for
many providers
Approach equipment
manufacturers to consider
discount coupon for purchase
of pneumatic otoscope heads
Recommendation 7. Children with persistent OME who are not at risk should be reexamined at 3- to 6-month
intervals until the effusion is no longer present, significant hearing loss is identified, or structural abnormalities
of the eardrum or middle ear are suspected.
Criterion failed / Barrier Specifics Suggested Remedy
11) The recommended action (what to do) is not
stated specifically and unambiguously (Executability)
22) The recommendation may not be compatible with
existing attitudes and beliefs of the guideline’s
intended users (Novelty/Innovation)
23) The recommendation may not be consistent with
patient expectations (Novelty/Innovation)
“3-6 month intervals” is
ambiguous
Surveillance without intervention
may not be compatible with
practitioner beliefs.
Surveillance without intervention
may not be compatible with
patient expectations
Define situations when each
interval in range is
appropriate
Include specific reference to
this topic in continuing
education offerings for coming
year.
Prepare leaflets/patient
education materials/ press
release that validate
surveillance decision.BMC Medical Informatics and Decision Making 2005, 5:23 http://www.biomedcentral.com/1472-6947/5/23
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a Workgroup Meeting of the HL7 Special Interest Group
(SIG) on Clinical Guidelines. The SIG includes represent-
atives from academia, vendors of electronic health record
software, and healthcare providers, who meet three times
each year to discuss standardization of guideline
components.
Judgments about the GLIA were obtained from 7 guide-
line implementers. Mean relevancy ratings by item ranged
from 2.7 to 4.0. On average, 26 of 30 items were rated as
"moderately" or "highly relevant." No reviewer used a rel-
evancy rating of 1 ("not at all relevant") for any item.
Mean clarity ratings by item ranged from 2.3 to 4.0. On
average, 29 of 30 items were rated as "clear" or "very
clear." The correlation of relevancy ratings and clarity
ratings by item was .23 (non-significant), indicating that
the two ratings of each item provided different
information.
Raters were also asked for suggestions about the items and
numerous comments were provided. Based on this feed-
back from implementers, GLIA was again revised. Items
that received low clarity or relevance scores were carefully
reviewed, definitions were clarified, and explanatory
material was added to better communicate the meaning
of the item. Based on suggestions from the reviewers, two
new items that explored recommendation sequencing
and the internal consistency of the guideline were added
to the Global dimension.
This process of obtaining judgment data from implement-
ers proved to be a rich source of ideas for refinement of
items. It also provided supportive evidence for the general
content validity of the developing instrument.
Step 4 -Review of ranked recommendations
Next, we used GLIA to formally assess the three recom-
mendations whose implementability had been ranked
previously by experts at the COGS Meeting (described
above in Step 1). Results using GLIA were consistent with
the earlier expert rankings, i.e., more critical implementa-
tion barriers were identified in the recommendation
ranked least implementable and no barriers were identi-
fied in the recommendation ranked most implementable.
Moreover, appraisal with GLIA allowed us to itemize spe-
cific obstacles, thereby clarifying particular impediments
to implementation in contrast to the global subjective
evaluation performed in Step 1.
This finding of agreement with expert rankings indicated
that GLIA results reflect the construct of implementability
as conceptualized by experts. This consistency provided
preliminary evidence that supports the construct validity
of GLIA assessments.
Step 5 – Application to a draft guideline from the American Academy 
of Pediatrics
To assess the value of application of GLIA in a real world
guideline development effort, we applied a late version of
the appraisal to a draft clinical guideline for the manage-
ment of otitis media with effusion (OME) that was in
preparation by a joint committee of national professional
societies – the American Academy of Pediatrics, the Amer-
ican Academy of Family Physicians, and the American
Academy of Otolaryngology. We received an intermediate
draft of the guideline for quality appraisal and evaluation
of implementability.
After independently rating the draft guideline, we met as
a group to discuss the barriers to implementation that we
identified. While not every barrier was identified by every
rater, no single barrier was uniquely identified. Remarka-
bly little discussion was needed to reach a consensus on
anticipated barriers to implementation.
Our report to the guideline authors identified several
instances of problems with decidability and executability
of individual recommendations. For example, the draft
recommended, "During the initial assessment of the child
with OME, the clinician should document (a detailed set
of physical findings)" (italics added). The GLIA report
drew attention to the fact that the guideline's users might
not consistently determine when in the course of contin-
uous care an assessment is initial. Adding to the confu-
sion, the draft guideline text later states that these findings
should be ascertained at every medical encounter. The rec-
ommendation that was ultimately published stated: "Cli-
nicians should document (the physical findings) at each
assessment of the child with OME." Vagueness was also
inherent in use of the terms "academic risk", "when nec-
essary", and "individualized management" without clear
definitions. Following the GLIA report, each of these was
clarified in the final guideline publication [22].
GLIA appraisal also identified extrinsic barriers to imple-
mentation that were reported to the Joint OME Imple-
mentation Committee of the professional societies. These
barriers included:
• Recommendations to perform pneumatic otoscopy,
tympanometry, hearing screening, and language assess-
ment would require acquisition of new equipment and
skills on the part of many physicians.
• Recommendations against prescription of antihista-
mines, decongestants, antimicrobials and corticosteroids
for effusions may not be compatible with patient
expectations.BMC Medical Informatics and Decision Making 2005, 5:23 http://www.biomedcentral.com/1472-6947/5/23
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The committee considered these potential barriers in their
design of a guideline implementation strategy.
Discussion
Many clinical guidelines – developed at substantial cost
and effort – have proven to be difficult or impossible to
operationalize. We developed the GuideLine Imple-
mentability Appraisal to facilitate guideline implementa-
tion. The instrument is designed to systematically
highlight barriers to implementation.
The GLIA is intended to provide feedback about a guide-
line's  implementability  to two distinct audiences: the
authors of the guideline and those individuals who
choose guidelines for application within a health care
delivery system. As a guideline is being developed, GLIA
can provide feedback to guideline authors about
potentially remediable defects. Developers may choose to
make modifications to the guideline document before it is
finalized and disseminated. Implementers can use GLIA
to help select a guideline, to identify potential obstacles,
and to target efforts toward addressing identified barriers.
Thus, GLIA can be used to help select guidelines that are
more easily implementable and also to devise implemen-
tation strategies that address identified barriers.
Two GLIA dimensions are of particular importance
because failure to address them adequately will result in
inconsistent implementation [23,24]. Any recommenda-
tion that does not clearly communicate what to do (i.e., it
fails executability criteria) or when to do it (i.e., fails
decidability criteria) is not fully ready for implementa-
tion. If possible, guideline authors should revise such a
recommendation before it is disseminated for implemen-
tation. If problems in decidability and executability are
not corrected prior to dissemination, different imple-
menters may well interpret the guideline authors' intent
in a discordant manner.
GLIA incorporates an optional dimension – computabil-
ity – to indicate the ease with which a recommendation
might be operationalized in an electronic information
system. Guideline implementation strategies – e.g., educa-
tion, academic detailing, audit and feedback, administra-
tive sanctions – need not necessarily involve computers
[25]. Because of the success of electronic implementations
in influencing clinician behavior [26-28], the wide varia-
tion in electronic information systems, and the current
lack of guidance regarding computability, these extrinsic
considerations were retained in the instrument. Items in
the  computability  dimension address the availability of
data to trigger the recommendation, the level of specificity
of the triggers and recommended actions, and whether
there is a clear path from recommendation to electronic
implementation.
Implementability must be differentiated from guideline
quality. Quality assessments relate primarily to determin-
ing the scientific validity of guidelines and, generally,
quality is assessed for the guideline as a whole. Imple-
mentability, on the other hand, is one component of
guideline quality, but its assessment is applied largely to
individual recommendations within a guideline.
In a comprehensive review of 13 tools for guideline qual-
ity appraisal, Graham [29] identified instruments devel-
oped by Cluzeau [14] and Shaneyfelt et al [16] as the best
developed. Since that time, the AGREE Instrument [15]
has emerged as the leading exemplar of guideline quality
appraisal and it has been endorsed by the Guidelines
International Network [30]. Application of GLIA can com-
plement quality appraisal in identifying guideline defi-
ciencies. Several GLIA items overlap with items in the
AGREE scale. However, to the best of our knowledge,
GLIA is the only tool that emphasizes implementation
concerns at the level of the individual recommendation.
Application of GLIA to measurement of decidability and
executability requires that users translate guideline recom-
mendations into statements comprising conditions and
actions [31]. Training and practice may be required to
assure consistency of logical analysis.
Application of GLIA requires team effort and a conse-
quent resource investment. The team that applies GLIA
should include members with skills in guideline imple-
mentation as well as members with specific understand-
ing of the clinical domain. Our experience has
demonstrated that rating a guideline that contains 15 rec-
ommendations might require several hours of an individ-
ual's time. Additional time must be spent in resolving
divergent ratings, although this effort usually yields an
improved understanding of implementation issues. We
are currently developing an electronic version of GLIA that
will provide a more efficient means of rating, scoring, and
reporting results.
During development, GLIA is best applied once evidence
has been synthesized and draft recommendations have
been formulated. When applied too late in the authoring
process, GLIA may have limited impact because authors
may have already become committed to recommenda-
tions as written and thus not open to making modifica-
tions. Assuring that guideline authors understand the
importance of implementability early on may help to
overcome premature commitment.
The classic challenge of instrument development is to
arrive at the correct number of items to minimize burden
and avoid redundancy, while including a sufficient
number to be comprehensive. GLIA contains 7 globalBMC Medical Informatics and Decision Making 2005, 5:23 http://www.biomedcentral.com/1472-6947/5/23
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items that are applied once to each guideline, 20 items
that are applied to each rated recommendation, and 4
optional items rating computability that are applicable
when an electronic implementation is planned. Further
use of GLIA is likely to result in clarification and perhaps
modification of the number of items.
Limitations
We have performed a series of activities to provide prelim-
inary evidence of GLIA's validity. However, neither the
inter-rater reliability of GLIA, the test-retest reliability, the
factor structure of the dimensions, nor its predictive valid-
ity has yet been established. Plans for this testing are
underway.
It should be noted that the authors performed the activi-
ties described as Step 4. Until verified by an independent
panel, these results should be considered preliminary and
subject to potential bias.
In addition, GLIA addresses primarily factors intrinsic to
the guideline. It is clear that extrinsic factors are critical in
a successful implementation. Future extensions to GLIA
will help to identify extrinsic barriers to implementation.
Conclusion
The GuideLine Implementability Appraisal provides a
tool designed to help developers and implementers better
understand and anticipate barriers to successful imple-
mentation. By aiding the design and operationalization of
highly implementable guidelines, our goal is that applica-
tion of GLIA may help improve health outcomes. Demon-
stration of GLIA's effectiveness will require prospective
testing.
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